liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy
Linköpings universitet, Institutionen för medicin och hälsa, Lungmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Centrum för kirurgi, ortopedi och cancervård, Lungmedicinska kliniken US. Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Allergicentrum US.
Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Centrum för hälso- och vårdutveckling, Regionalt cancercentrum.
Linköpings universitet, Institutionen för medicin och hälsa, Internmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Allergicentrum US.ORCID-id: 0000-0002-8365-3132
Uppsala University, Sweden .
Visa övriga samt affilieringar
2013 (Engelska)Ingår i: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 49, nr 1, s. 115-120Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. less thanbrgreater than less thanbrgreater thanMethods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. less thanbrgreater than less thanbrgreater thanResults: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). less thanbrgreater than less thanbrgreater thanConclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival.

Ort, förlag, år, upplaga, sidor
Elsevier , 2013. Vol. 49, nr 1, s. 115-120
Nyckelord [en]
Non-small cell lung cancer, Celecoxib, Chemotherapy, Survival, Plasma VEGF
Nationell ämneskategori
Medicin och hälsovetenskap
Identifikatorer
URN: urn:nbn:se:liu:diva-88362DOI: 10.1016/j.ejca.2012.07.032ISI: 000312896700015OAI: oai:DiVA.org:liu-88362DiVA, id: diva2:602881
Anmärkning

Funding Agencies|Ostergotland County Council, Medical Research Council of South-East Sweden (FORSS)||

Tillgänglig från: 2013-02-04 Skapad: 2013-02-04 Senast uppdaterad: 2017-12-06

Open Access i DiVA

fulltext(445 kB)576 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 445 kBChecksumma SHA-512
b53dc4663d954c5f94217dccae813337bcf8efbaebda2ad11a3e421178ac60697f3ad166259323f91c9a7a1bf00a9c51f0f5d2e7d74676bb4148eb9d0f10f5bc
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltext

Personposter BETA

Sörenson, SverreFohlin, HelenaLindgren, AndreaSederholm, ChristerClinchy, Birgitta

Sök vidare i DiVA

Av författaren/redaktören
Sörenson, SverreFohlin, HelenaLindgren, AndreaSederholm, ChristerClinchy, Birgitta
Av organisationen
LungmedicinHälsouniversitetetLungmedicinska kliniken USAllergicentrum USInstitutionen för klinisk och experimentell medicinRegionalt cancercentrumInternmedicin
I samma tidskrift
European Journal of Cancer
Medicin och hälsovetenskap

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 576 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 418 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf